Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility
- PMID: 24018924
- PMCID: PMC3979459
- DOI: 10.1086/673155
Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility
Abstract
Objective: Infections due to fluoroquinolone-resistant Escherichia coli (FQREC) are associated with significant morbidity and mortality. Fluoroquinolone resistance likely arises at the level of gastrointestinal colonization. The objective of this study was to identify risk factors for the development of FQREC gastrointestinal tract colonization in hospitalized patients, including the impact of antibiotics prescribed during hospitalization.
Design: A prospective cohort study was conducted from 2002 to 2004 within a university health system.
Methods: Hospitalized patients initially colonized with fluoroquinolone-susceptible E. coli were followed up with serial fecal sampling for new FQREC colonization or until hospital discharge or death. A Cox proportional hazards regression model was developed to identify risk factors for new FQREC colonization, with antibiotic exposure modeled as time-varying covariates.
Results: Of 395 subjects, 73 (18.5%) became newly colonized with FQREC. Length of stay before sampling (hazard ratio [HR], 1.02 [95% confidence interval (CI), 1.1-1.03]; P = .003) and malignancy (HR, 0.37 [95% CI, 0.21-0.67]; P = .001) were significantly associated with the development of FQREC colonization. In addition, receipt of a first-generation cephalosporin (HR, 1.19 [95% CI, 1.10-1.29]; P < .001) or cefepime (HR, 1.05 [95% CI, 1.00-1.10]; P = .048) during hospitalization increased the risk of new FQREC colonization.
Conclusions: The acquisition of FQREC in the hospital setting is complex, and antimicrobial stewardship programs should take into account patterns of antibiotic use in implementing strategies to reduce the development of new FQREC colonization. Future studies are needed to identify risk factors for infection in hospitalized patients newly colonized with FQREC.
Similar articles
-
Risk factors for the development of gastrointestinal colonization with fluoroquinolone-resistant Escherichia coli in residents of long-term care facilities.J Infect Dis. 2014 Feb 1;209(3):420-5. doi: 10.1093/infdis/jit471. Epub 2013 Aug 28. J Infect Dis. 2014. PMID: 23986544 Free PMC article.
-
Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance.Infect Control Hosp Epidemiol. 2009 Jan;30(1):18-24. doi: 10.1086/592703. Infect Control Hosp Epidemiol. 2009. PMID: 19046057 Free PMC article.
-
Temporal changes in resistance mechanisms in colonizing Escherichia coli isolates with reduced susceptibility to fluoroquinolones.Diagn Microbiol Infect Dis. 2013 Aug;76(4):491-6. doi: 10.1016/j.diagmicrobio.2013.04.018. Epub 2013 May 27. Diagn Microbiol Infect Dis. 2013. PMID: 23719087 Free PMC article.
-
Risk factors for efflux pump overexpression in fluoroquinolone-resistant Escherichia coli.J Infect Dis. 2012 Nov 15;206(10):1597-603. doi: 10.1093/infdis/jis567. Epub 2012 Sep 10. J Infect Dis. 2012. PMID: 22966123 Free PMC article.
-
Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions.Infect Control Hosp Epidemiol. 2013 Jan;34(1):40-8. doi: 10.1086/668780. Epub 2012 Nov 21. Infect Control Hosp Epidemiol. 2013. PMID: 23221191 Free PMC article. Review.
Cited by
-
Drug-resistant Enterobacteriaceae colonization is associated with healthcare utilization and antimicrobial use among inpatients in Pune, India.BMC Infect Dis. 2018 Oct 4;18(1):504. doi: 10.1186/s12879-018-3390-4. BMC Infect Dis. 2018. PMID: 30286741 Free PMC article.
-
Risk factors for quinolone-resistant Escherichia coli infection: a systematic review and meta-analysis.Antimicrob Resist Infect Control. 2020 Jan 9;9(1):11. doi: 10.1186/s13756-019-0675-3. eCollection 2020. Antimicrob Resist Infect Control. 2020. PMID: 31938541 Free PMC article.
-
Uptake of Ozenoxacin and Other Quinolones in Gram-Positive Bacteria.Int J Mol Sci. 2021 Dec 12;22(24):13363. doi: 10.3390/ijms222413363. Int J Mol Sci. 2021. PMID: 34948159 Free PMC article.
-
Outpatient Antibiotic Prescription.Dtsch Arztebl Int. 2016 Jul 1;113(26):454-9. doi: 10.3238/arztebl.2016.0454. Dtsch Arztebl Int. 2016. PMID: 27412990 Free PMC article.
-
High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous β-Lactams.Antimicrob Agents Chemother. 2020 Jan 27;64(2):e01415-19. doi: 10.1128/AAC.01415-19. Print 2020 Jan 27. Antimicrob Agents Chemother. 2020. PMID: 31767720 Free PMC article.
References
-
- Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118:259–268. - PubMed
-
- Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989–2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis. 2004;38:655–662. - PubMed
-
- Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis. 2005;41:923–929. - PubMed
-
- Chang TM, Lu PL, Li HH, Chang CY, Chen TC, Chang LL. Characterization of fluoroquinolone resistance mechanisms and their correlation with the degree of resistance to clinically used fluoroquinolones among Escherichia coli isolates. J Chemother. 2007;19:488–494. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical